Thailand's regenerative medicine framework, what changed in 2025.

Thailand has been a destination for regenerative medicine for the better part of a decade. The legal and regulatory framework around the practice has matured more recently, and 2025 brought several quiet but consequential updates that change what a credible clinic can and should offer. This is the framework as we read it from the inside of a PIC/S-GMP facility.

Who regulates what

Two bodies hold the practical authority. The Thai Food and Drug Administration (TFDA) regulates cell products, manufacturing facilities, and the import and export of biological material. The Medical Council of Thailand regulates the practice of medicine, the physician's scope, the consent process, and the standards a clinic must meet when administering investigational or off-label therapies.

The interaction matters. A treatment can be permitted by the Medical Council under physician judgement and informed consent, even where it has not received full TFDA registration as a marketed product, but only inside a facility that meets the TFDA's facility and quality standards. The framework rewards clinics that have actually done the PIC/S-GMP and ISO 15189 work; it does not reward clinics that have only claimed it.

What is approved versus what is permitted

A small number of cell-therapy indications are fully registered with the TFDA. A larger number sit in the category of permitted-with-conditions: legal to administer under a credentialled physician, in a qualifying facility, with documented consent and outcome tracking. This is the category most of our stem-cell technology programme operates within, and it is the category that requires the most careful patient-facing conversation about what the evidence supports.

Anything outside both categories is not legitimately offered as therapy in Thailand. If you encounter a clinic promoting a regenerative protocol that is neither registered nor permitted-with-conditions, you are encountering a regulatory problem, not a clinical decision.

What changed in 2025

Three updates this year are worth knowing about. First, the documentation standard for permitted-with-conditions therapies tightened: clinics are now expected to maintain prospective outcome registries for cell-therapy cohorts, not just retrospective consent files. This is a real lift for clinics that did not previously track outcomes systematically, and a non-issue for clinics that already do.

Second, the import-and-export rules for biological samples were clarified, with stricter conditions on transporting cell products between facilities. This pushes the practice further toward integrated clinics, where the cells are harvested, processed and administered in the same building, the way our Bangkok flagship is set up, and away from operators who outsource cell production to a third-party lab.

Third, the credentialling expectations for physicians administering cell therapy were formalised. A physician offering MSC therapy is now expected to demonstrate documented training in the modality, ongoing case review, and a referral relationship with a hematology consultant. This is where having a clinical team of nine specialists, including hematology, orthopaedics, cardiology, urology and aesthetic medicine, becomes a practical regulatory advantage as well as a clinical one.

What this means for the patient choosing a clinic

Ask three questions. One: is the therapy you are being offered registered, permitted-with-conditions, or something else, and ask to be shown the regulatory basis on which it is offered. Two: where is the cell product produced, and is it produced in the same facility where it will be administered. Three: which physician will be responsible for your case, and what specialty do they practise.

Most credible clinics will answer all three questions calmly. Some will give answers that do not quite line up with the regulatory framework as it actually stands. The questions are not aggressive, they are the same questions a patient would ask a hospital before any other significant procedure, and the regenerative-medicine market is mature enough that patients should expect them to be asked.

If you would like the broader regulatory context, why this framework exists at all, the foundational read is are stem cells available for retail purchase like other pharmaceuticals.